A pharmaceutical scientist and leader with a proven track record to deliver differentiated therapeutics. Experience spanning more than 25+ years of large pharma (Abbott, Lilly, Pharmacia, & Pfizer), biotechnology (DuPont Pharmaceuticals, Neuromed Pharmaceuticals), non-profit (Critical Path Institute) and academic service (University of Iowa, Cornell Medical College, Southern Illinois University School of Medicine) that resulted in 30+ drug candidates entering into clinical development to treat pain, neurological, psychiatric and urological disorders. Demonstrated ability to lead complex cross-functional matrix organizations of 100+ staff, and effectively manage $20M budgets within target. Ph3 and Launched Product Development experience with the following: Exalgo™(Oros-hydromorphone for OA & CLBP), Esreboxetine (DPNP), Dynastat™(acute pain), Lyrica™(neuropathic pain), Cymbalta™ (musculoskeletal pain, fibromyalgia, DPNP), Mirapex™(Parkinson's Disease, RLS) and Detrol™(overactive bladder). A leader that leverages global alliances and cross-organizational strengths to maximize organizational efficiencies (Merck, Recordati, Covance, NeuroSearch, RaQualia, Jubilant, Noxxon, Arteus, PsychoGenics, AnaBios, Chorus, Scripps, Univ of Pittsburgh, University of Colorado, University of Geneva, ORCATECH, Univ. of Arizona, Univ. of British Columbia, etc.). An medical educator experienced teaching medical students, graduate students, and neuroscience medical liaisons - currently Adjunct Professor of Pharmacology, SIU School of Medicine, and Research Professor of Medicine, University of Arizona. An accomplished author with 169 peer-reviewed articles, 18 chapters, 210 abstracts 1 book numerous IND submissions, as well as a co-inventor of 15 patents. A professional with a high aptitude for strategic, critical and tactical thinking that evaluates both scientific & business conditions resulting in effective solutions to challenges across diverse functions within the organization. President of Horizons Pharma Consulting, LLC, and Business Advisory Board member of ProNeurogen. of the development pipeline and therapeutic potential. In: Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities (eds. S.P. Arneric and J.D. Brioni), Wiley, New York, 1999. 15. Arneric, S.P. and Holladay, M.W, Agonists and antagonists of nicotinic acetylcholine receptors. In: Handbook of Experimental Pharmacology "Neuronal Nicotinic Receptors", (eds F. Clementi, C. Gotti, and D. Fornasari) Springer-Verlag, Heidelberg, 1999. 16. Arneric, S.P. Cholinergic approaches to treat pain. In: Pain: Current Understanding, Emerging Therapies and Novel Approaches to Drug Discovery. (eds. C. Bountra, R. Munglani, W.K. Schmidt ) Marcel Dekker, New York, 2003. pp. 749-762. 17. Arneric, S.P. and Sher, E., Current & Future Trends in Drug Discovery and Development Related to Nicotinic Receptors, In: Nicotine Receptors (edited by Dr. Robin Lester and Dr. Paul Kenny), 2014. 18. Stephenson, D.T. and Arneric, S.P., Advancing Regulatory Science Objectives and Biomarker Qualification Through Public-Private Partnerships Are Critical to Delivering Innovative Treatments for Brain Diseases, In: Translational Medicine in CNS Drug Development, Handbook of Behavioral Neuroscience, volume 25 (Edited by George G. Nomikos), Published 2019.
Description
